CNSP: CNS Pharmaceuticals, Inc. Stock

by  •  • Comments Off on CNSP: CNS Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 6.44
Enterprise Value ($M) -0.50
Book Value ($M) 3.35
Book Value / Share 0.07
Price / Book 1.92
NCAV ($M) 3.33
NCAV / Share 0.07
Price / NCAV 1.93

Profitability (mra)
Return on Invested Capital (ROIC) -5.04
Return on Assets (ROA) -7.33
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.82
Current Ratio 1.82

Balance Sheet (mrq) ($M)
Current Assets 7.39
Assets 7.41
Liabilities 4.06
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Armistice Capital, Llc 3.20 57.10
08-02 13D Cortice Biosciences, Inc. 5.70
07-02 13G Forster Robert 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September, 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13
2024-08-14 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June, 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15
2024-05-15 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March, 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 1
2024-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-22 1,868,455 8,564,291 21.82
2024-11-21 6,812,041 19,255,479 35.38
2024-11-20 2,731,064 7,263,151 37.60
2024-11-19 5,892,611 13,086,359 45.03

(click for more detail)

Similar Companies
CLNN – Clene Inc. CLRB – Cellectar Biosciences, Inc.
CMPX – Compass Therapeutics, Inc. CNTX – Context Therapeutics Inc.
COCP – Cocrystal Pharma, Inc.


Financial data and stock pages provided by
Fintel.io